Germany · Delayed Price · Currency is EUR Redcare Pharmacy NV Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 18% revenue growth to €849M, with strong Rx and non-Rx performance, improved EBITDA margin, and a rebound in German non-Rx. Guidance remains unchanged amid regulatory uncertainty and early-year volatility, with continued investment in IT and marketing optimization.
Fiscal Year 2025
-
Full-year revenues rose 24% to EUR 2.9 billion, driven by strong Rx growth and logistics expansion. 2026 guidance targets 13%-15% sales growth, Rx Germany revenues above EUR 670 million, and an adjusted EBITDA margin of at least 2.5%.
-
Sales grew 27% year-over-year with strong gains in both Rx and non-Rx segments, and adjusted EBITDA margin reached 2.1% year-to-date. Cash flow and liquidity remain robust, supporting ongoing investments in logistics and automation, while full-year guidance is reiterated.
-
Sales grew 27% year-over-year with record adjusted EBITDA and strong Rx momentum, especially in Germany. Guidance for over 25% sales growth and 2–2.5% EBITDA margin is confirmed, supported by regulatory wins and robust cash flow.
-
Group sales rose 28% year-over-year in Q1 2025, led by strong RX and ERX growth, with positive adjusted EBITDA and a growing customer base. Full-year guidance is reiterated, with profitability expected to improve as seasonality and marketing costs normalize.
Fiscal Year 2024
-
Sales grew 32% in 2024, with Rx sales up 64% and market leadership achieved in Germany and Italy. Adjusted EBITDA margin was 1.4%, and guidance for 2025 targets over 25% sales growth and a 2%-2.5% margin. Major logistics investments and regulatory factors remain key focus areas.
-
Sales grew 34% year-over-year to €1.7 billion, with strong eRx momentum in Germany and non-Rx growth at 20%. Adjusted EBITDA margin was 2.3% YTD, and market share in German eRx rose to 0.66% in October. Full-year sales guidance is €2.35–2.5 billion.
-
Q3 saw 21% organic sales growth and a surge in German Rx sales, driven by strong eRx adoption and high repeat order rates. Full-year sales guidance was raised, while EBITDA margin guidance was narrowed due to increased Rx marketing investments. Management remains confident in long-term growth and profitability.